---
layout: post
title: "Xellia Pharmaceuticals USA, LLC; Withdrawal of Approval of an Abbreviated New Drug Application for Bacitracin for Injection"
date: 2026-02-05 18:59:47 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-14680
original_published: 2022-07-11 00:00:00 +0000
significance: 8.00
---

# Xellia Pharmaceuticals USA, LLC; Withdrawal of Approval of an Abbreviated New Drug Application for Bacitracin for Injection

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** July 11, 2022 00:00 UTC
**Document Number:** 2022-14680

## Summary

The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is withdrawing the approval of an abbreviated new drug application (ANDA) for bacitracin for injection, 50,000 units/vial (ANDA 203177), held by Xellia Pharmaceuticals USA, LLC (Xellia). Xellia has requested withdrawal of approval of this application and has waived its opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/07/11/2022-14680/xellia-pharmaceuticals-usa-llc-withdrawal-of-approval-of-an-abbreviated-new-drug-application-for)
- API: https://www.federalregister.gov/api/v1/documents/2022-14680

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
